1. INTRODUCTION {#sec1}
===============

Selective small molecule agonists for the peroxisome proliferator-activated receptors *α* and *γ* are used to treat metabolic disorders. PPAR*α* agonists (fibrates) are used for their blood lipid lowering effects, and PPAR*γ* agonists (thiazolidinediones) for their insulin sensitizing effects \[[@B1]--[@B3]\]. Additionally, dual-acting agonists for PPAR*α* and PPAR*γ*, here termed PPAR*α*+*γ* agonists, have been shown to have clear therapeutic advantages over selective PPAR agonists in animals as well as humans \[[@B3], [@B4]\]. Unfortunately, a high percentage of PPAR*α*+*γ* agonists exhibited carcinogenic effect during preclinical safety testing in rats and mice \[[@B2]--[@B7]\]. Based on carcinogenicity findings for 6 PPAR*α*+*γ* and 5 PPAR*γ* anonymous developmental compounds in rats and mice, the FDA concluded that "PPAR agonists are multispecies, multistrain, multisex, multisite carcinogens" ([Table 1](#tab1){ref-type="table"}) \[[@B8]\]. The FDA further concluded that "mechanistic data to explain mode of action for tumour formation is not available. Tumours sites are consistent with the known distribution of PPAR receptors. Oncogenic potency correlates with PPAR agonist potency. A receptor-mediated mechanism cannot be ruled out" \[[@B8]\].

Accordingly, the attrition rate amongst developmental PPAR*α*+*γ* agonists has been high, with amongst others tesaglitazar (Galida), naveglitazar (LY519818), muraglitazar, ragaglitazar, farglitazar, and imiglitazar (TAK559) recently being discontinued due to clinical cardiac, kidney or liver toxicity, or preclinical findings \[[@B3]--[@B5]\]. These 6 developmental PPAR*α*+*γ* agonists represent different nonthiazolidinedione chemical structures, with different balances between PPAR*α* and *γ* activation \[[@B3], [@B5], [@B7], [@B9]\]. For 4 dual-acting agonists, preclinical carcinogenicity findings have been published muralitazar, ragalitazar, tesaglitazar, and naveglitazar are nongenotoxic by standard tests. Muralitazar caused gallbladder adenomas (male mice), adipocyte neoplasms (male and female rats), and urinary bladder tumours (male rats) \[[@B10]\]. Ragalitazar caused urinary bladder and renal pelvis tumours (male and female rats) \[[@B11]--[@B13]\]. Naveglitazar caused urinary bladder tumours in female rats, with the evaluation of carcinogenicity in male rats affected by poor survival \[[@B14]\]. Tesaglitazar caused mesenchymal sarcomas (male and female rats) \[[@B15]\].

The involvement of PPAR*α* and PPAR*γ* in cancer pathogenesis has been reviewed extensively \[[@B2], [@B5], [@B6], [@B16]--[@B20]\]. While PPAR*α* activation is clearly carcinogenic in rodents \[[@B21], [@B16], [@B17]\], the rodent PPAR*γ* data are controversial, and it appears that rodent PPAR*γ* activation may have oncogenic as well as tumour suppressor activity, likely depending amongst others on cellular and physiological contexts \[[@B5], [@B6], [@B8], [@B21], [@B18], [@B20]\]. Further, potential interactions between rodent PPAR*α* and PPAR*γ* in coexpressing cells have, to our knowledge, essentially not been examined at all. Finally, the human relevance of rodent data is unknown, as there is indication that, for example, PPAR*γ* agonists may have clinical benefit against certain human cancers such as lung cancer \[[@B22]\].

We base the present manuscript on the observation that in rats, toxicity of dual-acting PPAR*α*+*γ* agonists appears to target cells coexpressing PPAR*α* and PPAR*γ*, resulting in a qualitatively different target organ profile from that of selective PPAR*α* and PPAR*γ* agonists ([Table 1](#tab1){ref-type="table"}). Then, we review the literature with the aim of constructing a mode of action hypothesis for the carcinogenic effect of ragaglitazar in the rat urothelium. Due to the complexity of the available data, this is by definition speculative, and involves weighing of probablilities rather than combining facts, but the presented mode of action hypothesis forms the basis for our own research regarding the mechanisms by which PPAR agonists induce cancer in the rat urothelium.

2. COMPARING NORMAL PHYSIOLOGY OF PPARs IN THE RAT AND HUMAN UROTHELIUM: TOWARD SAFETY PPARallelograms {#sec2}
======================================================================================================

Expression of PPAR transcripts by urothelium occurs early in development and is conserved across species \[[@B24], [@B23]\], implying a tissue-specific role. In normal human urothelium, PPAR*γ* is most intensely expressed in the terminally differentiated superficial cell layer \[[@B25], [@B26]\], and expression is decreased in high-grade urothelial cell cancer \[[@B27]\], further indicating a potential role in urothelial cytodifferentiation.

Normal human urothelium isolated from urological specimens from patients with no history of urothelial cancer can be routinely established in serum-free primary cell culture and maintained through multiple serial subcultures (typically 6--10) as cell lines with a finite lifespan \[[@B28], [@B29]\]. These cultures show a regenerative phenotype and do not spontaneously express gene/proteins associated with late/terminal differentiation \[[@B28], [@B29]\].

Activation of PPAR*γ* by agonists (troglitazone or rosiglitazone) in finite cultures of normal human urothelial cells (NHU cell cultures) has been shown to induce expression of gene/protein markers associated with late/terminal urothelial differentiation, including uroplakins, cytokeratins, and tight junction constituents \[[@B26], [@B30]--[@B32]\]. The proposed differentiation-inducing mechanism is via PPAR*γ*-dependent transduction of intermediary transcription factors, including HNF3*α*, IRF-1, and FOXA1, and the induction of differentiation is specifically blocked by PPAR*γ* antagonists, or siRNAs against PPAR*γ*, IRF-1, and FOXA1 \[[@B32]\]. The induction of differentiation in NHU cell cultures by troglitazone requires inhibition of PI3K/AKT or MEK1/ERK signalling pathways downstream of EGFR \[[@B30]\], which in NHU cells is important for driving proliferation \[[@B33]\]. Inhibition of the downstream EGFR pathways resulted in dephosphorylation of PPAR*γ* \[[@B30]\]. The interaction between the signalling pathways that regulate differentiation (PPAR*γ*) and proliferation (EGFR) in urothelium may lie at the heart of regulating urothelial homeostasis and the switch from quiescent to regenerative phenotypes.

While PPAR*γ* activation in NHU cell cultures induces differentiation \[[@B26], [@B30]--[@B32]\], some selective PPAR*γ* and most dual-acting PPAR*α*+*γ* agonists cause bladder cancer in rats ([Table 1](#tab1){ref-type="table"}) \[[@B8], [@B34]\]. Also, a recent study showed that the specific PPAR*γ* agonist rosiglitazone is a strong promoter of hydroxybutyl(butyl)nitrosamine-induced bladder cancer in rats \[[@B35]\]. It is unknown whether this apparent contradiction represents a species difference, or a difference between in vivo and in vitro experimental systems. Also, it is well known that the outcome of PPAR*γ* signalling is highly context specific, that is, diametrally opposite biological effects can be seen in different situations \[[@B5], [@B6], [@B18], [@B20]\]. Resolution of the different observations in NHU cell cultures in vitro and rat tissue in vivo is of obvious relevance for elucidating the bladder carcinogenicity mechanisms of dual-acting PPAR*α*+*γ* agonists in rats, and elucidating the human relevance of the rat bladder cancer findings ([Table 1](#tab1){ref-type="table"}). Using a standard "safety parallelogram" approach for extrapolating the human relevance of rodent findings, PPAR signalling should be compared between rat urothelial cells in vivo and in vitro, and also between rat and human urothelial cells in vitro.

In this vein, we have recently compared normal rat and human urothelia in situ as well as following culture, and confirmed urothelial expression of all three PPARs and the RXR*α* and RXR*β* isoforms by immunolabelling. Some difference in relative expression and localisation of the different isoforms was apparent between species \[[@B36]\]. Also, rat urothelium exhibited a higher proliferative pool of Ki67 positive urothelial cells than did human urothelium \[[@B36]\], in agreement with a high percentage of G2/M cells in rat urothelium \[[@B13]\]. In contrast, human urothelial cells in situ appear arrested in G0/G1 \[[@B33]\]. The relevance of these differences between rat and human urothelia for PPAR signalling is at present unknown. However, PPAR and RXR expression patterns were retained by both NHU and cultured normal rat urothelial cells, opening the possibility that normal urothelial cell culture systems may be used to compare PPAR signalling between rats and humans \[[@B36], [@B28], [@B29], [@B37]\].

In short, most knowledge about PPAR*γ* signalling in urothelium stems from NHU cell cultures \[[@B26], [@B30]--[@B33]\], and very little information exists regarding PPAR*α* signalling response in the urothelium \[[@B38], [@B39]\]. Nevertheless, based on the observation that bladder cancer appears overrepresented for dual-acting PPAR*α*+*γ* agonists ([Table 1](#tab1){ref-type="table"}), and direct experimental indication of cross-talk between PPAR*α* and PPAR*γ* in urothelium as well as other cell types \[[@B42], [@B11], [@B40]--[@B43]\], our current hypothesis is that simultaneous activation of PPAR*α* and PPAR*γ* could in some way modulate the proliferation/differentiation balance, contributing to carcinogenesis of dual-acting PPAR*α*+*γ* agonists in the rat urothelium ([Figure 3](#fig3){ref-type="fig"}).

3. RANKING THE POSSIBLE MECHANISMS FOR THE CARCINOGENIC EFFECTS OF RAGAGLITAZAR AND NAVEGLITAZAR IN THE RAT UROTHELIUM: WHAT IS PPARt OF THE PPARcel? {#sec3}
=====================================================================================================================================================

Ragaglitazar is a phenyl propanoic acid derivative with dual PPAR*α*+*γ* agonist activity \[[@B44], [@B45]\]. In 2-year rat carcinogenicity assays, papillomas and carcinomas originating from the transitional epithelial (urothelial) lining of the urogenital tract were observed for all groups receiving ragaglitazar, for both male and female animals \[[@B12]\]. The urothelial papillomas and carcinomas were observed in the urinary bladder, ureters, and renal pelvis \[[@B12]\]. In mouse 2-year studies, one urinary bladder tumour was observed in a high-dose male mouse \[[@B12]\]. The higher sensitivity of rats than mice to urothelial tumours induced by ragaglitazar may be shared by other dual-acting PPAR*α*+*γ* agonists ([Table 1](#tab1){ref-type="table"}).

Four nonexclusive mechanisms were initially considered for the urothelial tumours in ragaglitazar-treated rats ([Figure 1](#fig1){ref-type="fig"}): (i) a receptor-mediated effect of the parent compound, with carcinogenesis caused by activation of PPAR*α* and *γ* transcription factors in the urothelium, that is, an exaggerated pharmacological effect, (ii) a genotoxic effect of metabolites of the parent compound (the parent compound itself is not genotoxic), (iii) a cytotoxic effect of parent compound or metabolites on urothelium, causing cancer due to a proliferation-driven chronic wound healing response, (iv) formation of urinary solids (urolithiasis) due to urinary changes induced by parent compound or metabolites, leading to cancer due to chronic irritation of the urothelium.

It is well known that certain agents cause urinary bladder cancer in rodents secondary to urolith formation \[[@B34]\], and that such carcinogenic effect is not relevant for humans because in humans uroliths do not predispose for bladder cancer \[[@B46]\]. A urolithiasis-mediated mechanism would be expected to affect primarily (albeit not exclusively) male rats due to the lower efficacy with which males void uroliths and act primarily in the ventral part of the urinary bladder ([Figure 1](#fig1){ref-type="fig"}) \[[@B34]\]. Therefore, a urolithiasis-mediated mechanism was ruled out primarily by the observation that ragalitazar caused tumours also in the ureters and renal pelvis, a conclusion supported by the occurrence of bladder tumours in females \[[@B12]\]. In detailed follow-up examinations in ragaglitazar-treated animals, urinary calculi were not detected during necropsy, no microcrystals were found to adhere to the urothelium by scanning electron microscopy, sediments were not increased in the urine by light microscopy, no significant changes were observed in urinary composition \[[@B12]\]. Likewise, and naveglitazar did not cause changes in urinary composition \[[@B14]\].

To explore mechanism (ii), profiling of urinary metabolites by mass spectroscopy and examination of DNA damage in urothelium isolated from ragaglitazar-treated rats by single-cell gel electrophoresis assay (COMET) were performed. Ragaglitazar exhibited multiple metabolites in rat urine (\>10), but there was low overall urinary excretion, and DNA damage was not observed in the urinary bladder of ragaglitazar-treated rats \[[@B12]\].

In summary, neither urinary calculi nor genotoxic damage by urinary metabolites could explain the carcinogenic effect of ragaglitazar in the rat urothelium. As a working hypothesis, we, therefore, assumed that ragaglitazar caused urothelial cancers in rats by a receptor-mediated effect of the parent compound (mechanism (i) above), which may be exacerbated by a cytotoxic effect of parent compound or metabolites on urothelium, promoting a chronic wound healing response (mechanism (iii) above). This mode of action hypothesis ([Figure 3](#fig3){ref-type="fig"}), comprising 2 nonexclusive mechanisms ([Figure 1(b)](#fig1){ref-type="fig"}, (i) and (iii)) was in agreement with coexpression of PPAR*α* and *γ* by the urothelium \[[@B24], [@B36], [@B23]\], with the known propensity of various PPAR agonists to exhibit cytotoxic effects \[[@B20], [@B47], [@B48]\], and with the known positive correlation between cytotoxic and carcinogenic effects for some small molecule drugs \[[@B49], [@B50]\]. Similarly, it was concluded for naveglitazar-induced bladder cancer in rats that a mechanism involving a direct effect of the compound on PPARs in the urothelium should be considered \[[@B14]\].

4. EARLY BIOMARKERS FOR RAGAGLITAZAR AND NAVEGLITAZAR ACTIONS IN THE RAT UROTHELIUM {#sec4}
===================================================================================

The mode of action hypothesis detailed above ([Figure 3](#fig3){ref-type="fig"}) predicted that very early (precancerous) changes should occur in the urothelium of ragaglitazar-dosed rats, reflecting exaggerated pharmacology and/or cytotoxicity of the compound.

To test whether this was the case, a method was developed where a lysing guanidine buffer is injected in situ in the bladder of anaesthetised treated animals, providing selective lysis of the urothelial layer and minimizing the risk of preparation artefacts ([Figure 2](#fig2){ref-type="fig"}).

Such urothelial lysates from male rats dosed orally for 2-3 weeks were examined by a combination of microarray, RT-PCR, and Western blotting methods \[[@B11]\]. We found that within 4 days of ragaglitazar treatment, the transcription factor Egr-1 was strongly upregulated in the bladder urothelium of animals treated with 50 mg/kg/day ragaglitazar \[[@B11]\]. Interestingly, Egr-1 was not upregulated in the bladder urothelium of rats daily receiving either 8 mg/kg/day rosiglitazone (a selective PPAR*γ* agonist) or 200 mg/kg/day fenofibrate (a selective PPAR*α* agonist), but appeared upregulated in the bladder urothelium of rats receiving a combination of rosiglitazone and fenofibrate \[[@B11]\]. The significance of these findings is being confirmed, but the data support that in rats orally dosed with ragaglitazar, expression of Egr-1 was acutely induced in the bladder urothelium, and coactivation of PPAR*γ* and PPAR*α* was required for this. Other early changes observed in the bladder urothelium involved phosphorylation of the S6 ribosomal protein, and the c-jun transcription factor \[[@B11]\].

Microscopically, hypertrophy (increased cell size), hyperplasia (increased number of cells), and increased proliferation (increased DNA synthesis, measured by BrdU incorporation) were observed in the bladder and kidney pelvis urothelium of ragaglitazar-dosed rats, within 3 weeks of daily oral dosing \[[@B11]--[@B13]\]. Because urothelial hypertrophy is difficult to quantitate by light microscopy, we utilized flow cytometry as well as DNA/protein measurements to show that within 2-3 weeks of oral dosing with 5--50 mg/kg/day ragaglitazar, the bladder urothelium underwent diffuse, generalized hypertrophy; that is, the hypertrophy affected the whole urothelial cell population \[[@B13]\]. Urothelial hypertrophy was also observed in the kidney pelvis \[[@B12], [@B13]\]. Finally, hypertrophy and hyperplasia were likewise observed in the urothelium of ragaglitazar-dosed dogs and monkeys \[[@B12]\]. Interestingly, in naveglitazar-dosed rats, urothelial hypertrophy was the earliest change, seen at 27 weeks, followed by urothelial hyperplasia at 53--79 weeks \[[@B14]\].

5. POTENTIAL RELEVANCE OF EARLY UROTHELIAL CHANGES FOR LATER CANCER DEVELOPMENT {#sec5}
===============================================================================

The c-jun transcription factor is a recognized oncogene \[[@B51]\] and has been implicated in human bladder cancer development \[[@B52], [@B53]\]. Futhermore, increased c-jun activity has been linked to bladder cancer development in mice exposed to the model bladder carcinogen arsenic \[[@B52], [@B53]\].

Egr-1 (Zif268) is a zinc finger transcription factor mediating a broad range of cellular responses such as proliferation, differentiation, apoptosis, neuronal plasticity, and neovascularization \[[@B54]--[@B57]\]. Egr-1 is closely related to the WT1 Wilms\' tumour suppressor, with these two zinc finger transcription factors being able to be bound to the same DNA sequence, but exerting opposite effects on transcription \[[@B58]--[@B60]\]. Given the importance of the WT1 transcription factor for kidney development \[[@B61]\], it is perhaps unsurprising that Egr-1 also has functional roles through the length of the urogenital tract. Egr-1 expression is regulated during kidney development \[[@B62]\], and postnatally, Egr-1 is involved in control of kidney function \[[@B63]\], and bladder urothelium function \[[@B64]--[@B66]\]. Egr-1 overexpression and interaction with the WT1 Wilms\' tumour suppressor may be involved in the pathogenesis of nephroblastoma \[[@B58]--[@B60]\]. Further, the bladder and prostate epithelia are contiguous and have common embryological origin \[[@B61], [@B67], [@B68]\], and interestingly, Egr-1 is absolutely required for the development of prostate cancer in a mouse model \[[@B69], [@B70]\]. Egr-1 has also been implicated in human prostate cancer development \[[@B71]\]. In vitro, Egr-1 is induced in human urothelial cancer cells treated with the model bladder carcinogen arsenic \[[@B53]\], and Egr-1 physically associates with BLCA-4, a recognized marker of bladder cancer, in human urothelial tumour cells \[[@B72], [@B73]\]. c-jun and Egr-1 have also been shown to physically interact in rat spontaneous pheochromocytoma PC12 cells \[[@B56]\]. Importantly, it is currently unknown whether the phosphorylation of c-jun and induction of Egr-1 in the urothelium of ragaglitazar-treated rats correspond to increased activity of these transcription factors.

Hypertrophy (increased cell size) is a surrogate parameter for increased protein synthesis (translation) \[[@B74]\]. Intriguingly, phosphorylation of the ribosomal S6 protein is known to stimulate protein translation, and S6 phosphorylation is also linked to cellular size \[[@B75]--[@B80]\]. Thus, the increased S6 phosphorylation and hypertrophy observed in the urothelium of ragaglitazar-treated rats may be causally linked \[[@B11], [@B13]\]. As mentioned, hypertrophy was also the earliest change in the urothelium of naveglitazar-dosed rats \[[@B14]\].

Urothelial hypertrophy can also be induced by noncarcinogenic agents \[[@B81]\]. Nevertheless, both hypertrophy and increased protein synthesis have been reported as precancerous changes following exposure to model bladder carcinogens \[[@B82]\], and translational deregulation is increasingly being recognized as playing a key role in cancer development \[[@B75]--[@B77], [@B80], [@B83]\].

In summary, while completely speculative, a causal link between early urothelial changes (hypertrophy, S6 phosphorylation, c-jun phosphorylation, Egr-1 induction) and later urothelial cancer development in ragaglitazar-treated rats appears possible ([Figure 3](#fig3){ref-type="fig"}). As mentioned above, early urothelial hypertrophy was also observed in naveglitazar-dosed rats \[[@B14]\].

6. CYTOTOXIC AND NONGENOMIC EFFECTS OF PPAR AGONISTS IN VITRO {#sec6}
=============================================================

Surprisingly, structurally different agonists for PPAR*α* and PPAR*γ* show a common propensity for PPAR-independent (off-target) effects, particularly relating to growth inhibition (cytostasis) and cell death in a variety of cell types \[[@B20], [@B48], [@B84], [@B85]\]. The mechanisms for the nongenomic actions of PPAR agonists are unknown, but may have parallels in, for example, the nongenomic actions of steroid hormones \[[@B86]\].

We found that exposure of NHU cultures to ciglitazone or troglitazone (PPAR*γ*) or ragaglitazar (PPAR*α*+*γ*) rapidly induced apoptosis in NHU cells \[[@B47]\]. These effects were independent of p38 or pERK activation and were not seen with fenofibrate (PPAR*α*), L165041 (PPAR*β*), or rosiglitazone (PPAR*γ*). Proapoptotic agonists induced rapid, sustained increases in intracellular calcium that were attenuated by removal of extracellular calcium, indicating the involvement of store-operated calcium entry. Proapoptotic agonists also induced cell membrane disruption, loss of mitochondrial membrane potential, and activation of caspases-9 and -3. PPAR agonist-induced apoptosis was partially attenuated by store-operated calcium channel inhibitors, but was unaffected by PPAR*γ* antagonists. This demonstrates that structurally different PPAR agonists activate intrinsic apoptotic pathways in normal human urothelial cells in a PPAR-independent manner. Interestingly, PPAR agonists associated with hepatotoxicity and carcinogenicity in vivo also exhibited the most severe cytotoxicity profile in vitro, comprising apoptosis and sustained increases in intracellular calcium \[[@B47]\]. Recently, sustained increases in intracellular calcium were linked to transactivation of the EGF receptor by nongenomic actions of PPAR*γ* agonists \[[@B85]\].

Because the nongenomic cytotoxic actions of PPAR agonists appear to be relatively cell type independent \[[@B48]\], and because it is well known that cytotoxic effect in vitro may positively correlate with a carcinogenic effect in vivo \[[@B49], [@B50]\], we currently favor incorporating the NHU cytotoxicity findings \[[@B47]\] into a mode of action hypothesis for the carcinogenic effect of dual-acting PPAR*α*+*γ* agonist in the rat urothelium ([Figure 3](#fig3){ref-type="fig"}). Interestingly, normal urothelial cells are more sensitive to the nongenomic cytotoxic actions of PPAR agonists than are transformed urothelial cells \[[@B27]\]. Thus, nongenomic cytotoxic actions could hypothetically contribute not only to initiating the carcinogenic process (detailed in [Figure 3](#fig3){ref-type="fig"}) but also to selecting transformed urothelial cells.

Intriguingly, and further complicating matters, some studies suggest that PPAR*γ* agonists previously associated with nongenomic cytotoxicity at high concentration can at lower concentrations stimulate proliferation and prevent apoptosis \[[@B6], [@B18], [@B87]--[@B90]\]. This stimulatory effect does not occur for PPAR*γ* agonists in NHU cultures \[[@B91]\], but weak stimulatory effects and bell-shaped responses have been observed with unsaturated fatty acids in NHU cultures \[[@B92]\]. In short, because bell-shaped responses from activation of a specific PPAR may be related to agonist characteristics, and because detection of weak mitogenic responses in cell cultures (at low drug concentrations) may technically be more difficult than detection of cytotoxicity in cell cultures (at high drug concentrations), the phenomenon of bell-shaped response curves encompassing mitogenic as well as cytotoxic effects may be underreported in studies of PPAR agonist effects in vitro.

7. RECEPTOR-MEDIATED CARCINOGENESIS IN RAT UROTHELIUM BY DUAL-ACTING *α*+*γ* AGONISTS SUCH AS RAGAGLITAZAR: PPARadigm OR PPARadox {#sec7}
=================================================================================================================================

The dual-acting PPAR*α*+*γ* agonist muraglitazar also caused urothelial tumours in rats, but in this case it was concluded that a urolithiasis-mediated mechanism was responsible \[[@B10], [@B12], [@B93], [@B94]\]. In contrast, uroliths were not involved in the urothelial cancers seen in ragaglitazar or naveglitazar-treated rats \[[@B12], [@B14]\]. Furthermore, tesaglitazar did not induce bladder cancers in rats \[[@B15]\]. The reasons for the difference in carcinogenic potential in the rat urothelium for the four dual-acting PPAR*α*+*γ* agonists muraglitazar, ragaglitazar, naveglitazar, and tesaglitazar are unknown. It is tempting to speculate that the differences in PPAR affinity and selectivity between these three PPAR*α*+*γ* agonists influence carcinogenic potential in the rat urothelium \[[@B3], [@B5], [@B9]\]. PPAR*α* and PPAR*γ* activation profiles can be compiled for muraglitazar, ragaglitazar, naveglitazar, and tesaglitazar from different studies \[[@B3], [@B5]\]. However, in order to evaluate whether PPAR affinity and selectivity correlates with carcinogenicity, we believe it would be required to compare these dual-acting PPAR*α*+*γ* agonists in the same study, preferably using urothelial cells and monitoring the activation of endogenous PPAR*α* and PPAR*γ* which are coexpressed in this cell type. Technically, this could, for example, be done by, in urothelial cells, separately monitoring expression of genes known to be activated by PPAR*α* on one hand, and genes known to be activated by PPAR*γ*, on the other (PPAR-regulated genes listed in \[[@B95]\]). Such data unfortunately do not exist. Nevertheless, the findings in [Table 1](#tab1){ref-type="table"} suggest that while agonists with a high degree of PPAR*γ* selectivity (i.e., specific PPAR*γ* agonists) can cause bladder cancer in rats, they may be less prone to do so than are agonists with a lower degree of PPAR*γ* selectivity (i.e., dual-acting PPAR*α*+*γ* agonists). This interpretation of the data in [Table 1](#tab1){ref-type="table"} is speculative (disregards, e.g., dose level or PPAR agonist efficacy differences between the animal trials with the listed agents), but is plausible given the relatively unique coexpression of PPAR*α* and PPAR*γ* by urothelial cells. Thus, the hypothesis deserves further exploration, that combined PPAR*α*+*γ* activation, by agents with low PPAR*γ* selectivity or high doses of agents with high PPAR*γ* selectivity, may predispose to urothelial cancer in rats by receptor-mediated mechanisms ([Figure 3](#fig3){ref-type="fig"}).

It has been proposed that it is unlikely that any of the urothelial cancers observed in rats treated with dual-acting PPAR*α*+*γ* agonists are due to receptor-mediated effects (exaggerated pharmacology) \[[@B34]\]. We have a different interpretation of the available data: it is clear that activation of PPAR*α* can cause tumours in rats and mice ([Table 1](#tab1){ref-type="table"}) \[[@B21]\], and while more controversial, activation of PPAR*γ* can at least in some cases cause cancer in rats and mice ([Table 1](#tab1){ref-type="table"}) \[[@B5], [@B6], [@B8], [@B18], [@B20]\]. Of special interest is the recent finding that selective PPAR*γ* agonists such as rosiglitazone can promote hydroxybutyl(butyl)nitrosamine-induced bladder cancer in rats \[[@B35]\] ([Table 1](#tab1){ref-type="table"}). Thus, it is plausible that the carcinogenic effect of dual-acting PPAR*α*+*γ* agonists in cells coexpressing PPAR*α* and PPAR*γ* ([Table 1](#tab1){ref-type="table"}) may be due to receptor-mediated mechanisms (exaggerated pharmacology). Further, it has been described that PPAR*α* and PPAR*γ* agonists may exhibit synergistic effects in cells coexpressing PPAR*α* and PPAR*γ* \[[@B42], [@B11], [@B40]--[@B43]\]. Thus, the hypothesis of receptor-mediated carcinogenicity (carcinogenicity due to exaggerated pharmacology) would predict that in rat tissue coexpressing PPAR*α* and PPAR*γ*, dual-acting PPAR*α*+*γ* agonists may have a higher propensity for carcinogenic effect than selective PPAR*α* and PPAR*γ* agonists alone, which in fact appears to be the case ([Table 1](#tab1){ref-type="table"}). Endothelial cells also coexpress PPAR*α* and PPAR*γ* \[[@B96]\], and synergy between PPAR*α* and PPAR*γ* in the endothelium has been described \[[@B42]\], but hemangiosarcoma frequencies appear comparable between mice treated with dual-acting PPAR*α*+*γ* agonists and selective PPAR*γ* agonists ([Table 1](#tab1){ref-type="table"}). This may relate to differences between mouse urothelium and endothelium in PPAR*α* and PPAR*γ* expression, signalling, and/or cross-talk.

Specifically, we are not aware of any data that a priori disqualifies a receptor-mediated carcinogenicity mechanism for dual-acting PPAR*α*+*γ* agonists in the rat urothelium \[[@B34]\]. For example, (human) urothelium does not appear to receive growth/differentiation cues from the urine \[[@B25]\] and hence low urinary excretion of PPAR agonists does not rule out receptor-mediated carcinogenic effects. Also, the well known in vitro cytotoxic effects of PPAR agonists \[[@B5], [@B6], [@B20], [@B48]\], including ragaglitazar \[[@B47]\], are generally mediated by nongenomic (off-target) mechanisms, that is, do not rule out receptor-mediated carcinogenic effects in vivo. In fact, our current working hypothesis for ragaglitazar is that exaggerated pharmacology and nongenomic cytotoxicity may occur simulaneously and together promote cancer development in the rat urothelium ([Figure 3](#fig3){ref-type="fig"}). Finally, the overrepresentation of bladder cancers in male rats seen with some dual-acting PPAR*α*+*γ* agonists is sometimes presented as an argument against receptor-mediated carcinogenic effects \[[@B34]\]. However, current data suggests that there are gender differences in the expression of all PPAR isoforms, in a variety of species and tissue, including the urinary bladder \[[@B97]--[@B102]\]. Moreover, our hypothesis implies that the male rat may represent an accelerated tumour model, as any cytotoxicity/damage to the urothelium will provoke urothelial regeneration and thus promote a receptor-mediated carcinogenic effect ([Figure 3](#fig3){ref-type="fig"}).

A key issue for the future will be how to distinguish between "receptor-mediated" and "nonreceptor-mediated" urinary bladder carcinogenicity mechanisms in rat experiments. Most simply, we suggest that receptor-mediated (exaggerated pharmacology) carcinogenicity mechanisms may be suspected for dual-acting agonists that induce carcinogenicity-relevant biomarkers in the rat urothelium with rapid kinetics (i.e., following a minimum of repeated oral doses) and with equal distribution in the dorsal and ventral bladder domes \[[@B11]--[@B13]\]. The maximal doses in this type of study could logically be the same as those used for 2-year rat carcinogenicity studies (heart weight increases of approx. 25% at 13 weeks have been suggested to identify the maximum tolerated dose for 2-year rodent oncogenicity studies) \[[@B8]\], and lower doses may allow evaluation of nongenomic (off-target) effects on the biomarker endpoints \[[@B13]\]. Further refinement may be accomplished by including PPAR*α* and PPAR*γ* antagonists \[[@B95], [@B103], [@B104]\], inactive analogs \[[@B85]\], or, more speculatively, modulation of PPAR expression in the bladder by siRNA approaches \[[@B105]\].

Adding 1% NH~4~Cl to rat feed induces systemic acidosis, measurable directly by reduced blood pH, reduced blood \[HCO~3~ ^−^\], and increased blood \[H^+^\] as well as indirectly by, for example, increased urinary Ca^++^ and phosphorus excretion due to bone resorption \[[@B106]\]. As urine acidification also occurs, adding 1% NH~4~Cl to rat feed is sometimes used to evaluate whether rat bladder carcinogenesis is urolith-mediated \[[@B12], [@B34], [@B93], [@B94]\]. However, urine acidification by feeding rats NH~4~Cl has also been reported to reduce the occurence of bladder tumours, where the mechanism is not thought to be urolith-mediated \[[@B107]--[@B109]\], and NH~4~Cl feeding of rats can also influence the occurrence of tumours outside of the urinary bladder \[[@B110]\]. In fact, systemic acidosis induced by NH~4~Cl would be expected to have profound effects on cellular and organ function in the whole organism, including the bladder \[[@B110]--[@B116]\]. Therefore, while some aspects of bladder function are unaffected by NH~4~Cl feeding \[[@B117]\], the impact of systemic acidosis on bladder cancer development may be unrelated to urolith formation. Further, it is possible that induction of acidosis may directly interfere with the action of some PPAR agonists \[[@B118]--[@B121]\]. In short, induction of systemic acidosis may not specifically discriminate between mechanisms of PPAR carcinogenicity in the rat urothelium ([Figure 1](#fig1){ref-type="fig"}).

8. CURRENT MECHANISM HYPOTHESIS FOR UROTHELIAL CANCERS INDUCED BY DUAL-ACTING PPAR AGONISTS IN THE RAT {#sec8}
======================================================================================================

We have attempted to integrate the urothelial changes observed in ragaglitazar-treated rats \[[@B11]--[@B13]\], results from ragaglitazar-treated urothelial cell cultures \[[@B47]\], knowledge about PPARs in urothelial biology (see [Figure 3](#fig3){ref-type="fig"}), and new data about PPAR isoform expression in rat and human bladder \[[@B36]\] into a mode of action hypothesis for urothelial carcinogenesis by dual-acting PPAR agonsts in rat urothelium ([Figure 3](#fig3){ref-type="fig"}).

The hypothesis is completely speculative ([Figure 3](#fig3){ref-type="fig"}), but to our knowledge, does not conflict with current knowledge of PPAR biology (see [Figure 3](#fig3){ref-type="fig"}). The main predictions of the hypothesis are that (i) coactivation of PPAR*α* and PPAR*γ* in the rat urothelium can produce effects different from those observed with specific activation of either PPAR*α* or PPAR*γ*, (ii) the effects of dual-acting PPAR*α*+*γ* agonists on early biomarkers (e.g., Egr-1) depend on structural aspects such as PPAR selectivity, affinity, and activating effect of the agonist, and (iii) early biomarker changes (e.g., Egr-1 induction, phosphorylation of c-jun and S6) are causally involved in later urothelial cancer development.

For practical reasons, our focus is on early (precancerous) changes in the rat bladder urothelium ([Figure 3](#fig3){ref-type="fig"}), but involvement of PPARs in later stages of urothelial cancer progression is also possible by paracrine \[[@B38]\] or immunological mechanisms \[[@B19]\].

9. FUTURE DIRECTIONS {#sec9}
====================

In practical experimental terms, based on the mode of action hypothesis presented in [Figure 3](#fig3){ref-type="fig"}, we currently prioritize (i) evaluating cross-talk between PPAR*α* and PPAR*γ* signalling in urothelial cells, by treating rats orally with rosiglitazone and fenofibrate either separately or in combination with short-term studies \[[@B11]\], (ii) evaluating the causal role of Egr-1 in urothelial cancer development by, for example, chromatin immunoprecipitation experiments from rat bladder, and (iii) comparing the findings between rat urothelium in vivo and finite cultures of normal rat and human urothelial cell in vitro.

Specifically, we believe that establishing cause-effect relationships between early biomarkers and later cancer development is key to understand the mode of action for carcinogenic effects of dual-acting PPAR*α*+*γ* agonists in the rat urothelium ([Figure 3](#fig3){ref-type="fig"}). Validating early carcinogenicity biomarkers in rats should also allow developing simple preclinical assays to rank the carcinogenic potential of developmental PPAR agonists ([Figure 3](#fig3){ref-type="fig"}). Additionally, understanding the mechanisms in rats ([Figure 3](#fig3){ref-type="fig"}) would aid in assessing the human relevance of the rat bladder cancer findings \[[@B122], [@B123]\].

Finally, a recent study showed that the specific PPAR*γ* agonist rosiglitazone is a strong promoter of hydroxybutyl(butyl)nitrosamine-induced bladder cancer in rats \[[@B35]\]. It is tempting, but obviously highly speculative, to integrate this obervation into the proposed mode of action hypothesis for ragaglitazar-induced bladder cancers in rats ([Figure 3](#fig3){ref-type="fig"}). The prediction would be that in the rat urothelium in vivo, PPAR*α* activation may provide cancer initiation and PPAR*γ* activation cancer promotion signals. A plausible cancer initiation mechanism by PPAR*α* activation is peroxisome formation and free radical production. Thus, exploring the effects of specific PPAR*α* agonists in the rat urothelium would seem a highly worthwhile undertaking.

Hanne Vikjær Andersen is thanked for facilitating the rat experiments; Amanda J. Nicholl, Pettit, Bikramjit Chopra, and Niels Brünner are thanked for helpfull discussions; Trine B. Cohn, Lis S. Sørensen, Ulla K. Thinggaard, and Linda E. Pedersen are thanked for help with animal experiments; J. Southgate is supported by York Against Cancer.
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:   Protein kinase B
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:   Epidermal growth factor receptor

Egr-1:

:   Zif268, early growth response protein 1, zinc finger transcription factor

FOXA1:

:   Forkhead box A1

HNF-3 alpha:

:   Hepatocyte nuclear factor-3 alpha, winged helix transcription factor

IRF-1:

:   Interferon regulatory factor 1

NHU:

:   Finite normal human urothelial cell lines

PPAR:

:   Peroxisome proliferator-activated receptor

PI3K:

:   Phosphatidyl inositol 3 kinase

S6:

:   Ribosomal protein.

![*Possible mechanisms for the carcinogenic effect of dual-acting PPAR*α*+*γ* agonists in the rat urothelium.* (a) Simplified view of the rat urinary tract, showing the urothelial lining of urinary bladder, ureters, and kidney pelvis. The star in the bladder lumen indicates the expected predilection site for urolith residence, the ventral part of the bladder. In the shown part of the urogenital tract, there are no gross anatomical differences between male and female rats. The epithelial lining is contiguous but exhibits differentiation differences through the urogenital tract \[[@B61], [@B138]\]. The drawing is not to scale. (b) Four possible mechanisms for carcinogenic effect in rat urothelium by dual-acting PPAR*α*+*γ* agonist.](PPAR2008-103167.001){#fig1}

![*Lysis of the rat bladder urothelial cell layer in situ*. (a), (b) On a fully anesthetized rat, the bladder is exposed through an abdominal incision, a thin needle or catheter (27G) is introduced into the bladder at the bladder neck, and ligated in place with a silk suture. (c) The bladder is emptied for urine, and filled with approximately 0.5 mL lysis solution (4 M guanidine isothiocynate, 0.5% sarcosine, 25 mM citrate, pH 5.5), which is left in place for 2 minutes and withdrawn. The resulting urothelial lysates can be used for RNA isolation or protein analysis by Western, as described in \[[@B11]\]. By infusing a trypsin solution into the bladder lumen, suspensions of urothelial cells for flow cytometric analysis can be made \[[@B13]\].](PPAR2008-103167.002){#fig2}

![*Current mode-of-action hypothesis for the carcinogenic effect of dual-acting PPAR*α*+*γ* agonists in the rat urothelium.* To explain the carcinogenicity of dual-acting PPAR*α*+*γ* agonists in the rat urothelium, we favor a multifactorial mode-of-action (MOA) hypothesis, compatible with the observation that PPAR agonists can cause diametrally opposite biological effects (mitogenesis as well as cytotoxicity in vitro, carcinogenicity as well as tumour inhibition in vivo) depending on context (species, PPAR activation profile of agonist, agonist dose, cell type as well as PPAR expression, etc.) \[[@B2], [@B4]--[@B6], [@B8], [@B17]--[@B20], [@B48], [@B127], [@B144]\]. (The shown MOA hypothesis is based on previously published ragaglitazar data \[[@B36], [@B11]--[@B13], [@B47]\], but may be applicable to other dual-acting agonists ([Table 1](#tab1){ref-type="table"}) \[[@B8], [@B14]\]. The shown MOA hypothesis is applicable to rats only due to the known profound species differences in PPAR function \[[@B136], [@B16]\]. Bladder cancer was seen in SD, Wistar, and Fischer rats of both sexes \[[@B8], [@B12]\], but the shown MOA hypothesis may nevertheless be rat strain dependent due to rodent strain differences in PPAR function \[[@B124]\]. The shown MOA hypothesis is compatible with gender differences, due to gender differences in PPAR expression and function \[[@B97]--[@B102]\], and does not assume urinary excretion of the PPAR agonist \[[@B25]\].)](PPAR2008-103167.003){#fig3}

###### 

Frequency of cancer findings for PPAR agonists in rats, mice, and hamsters. The table is adapted from \[[@B8]--[@B124]\] and comprises rodent carcinogenicity data for between 16 and 30 PPAR*α* agonists (pharmacological as well as industrial compounds) \[[@B21], [@B124]\], 5 PPAR*γ* agonists (pharmacological compounds only) \[[@B8]\], and 6 dual-acting PPAR*α*+*γ* agonists (pharmacological compounds only) \[[@B8]\]. Numbers in the cells: number of compounds causing the indicated pathology in the indicated rodent species; M: male; F: female. The difference in rodent bladder and liver tumour frequency between PPAR*α*, PPAR*γ*, and PPAR*α*+*γ* agonists is significant (*P* \< .0001, Chi-square test). The difference in rodent bladder cancer frequency betwen PPAR*γ* and dual-acting PPAR*α*+*γ* agonists is borderline significant (*P* = .0357 and .081 by Chi-square and Fischer\'s exact tests, resp.).

  ^(a)^PPAR agonist selectivity (*n*, number of compounds)                                     ^(b),(f)^Hemangio-sarcoma       ^(c),(f)^Urinary bladder and renal pelvis   ^(d)^Fibrosarcoma   ^(f)^Lipoma and sarcoma   ^(e),(f)^Liver              Other
  -------------------------------------------------------------------------------------------- ------------------------------- ------------------------------------------- ------------------- ------------------------- --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  *PPAR*α* agonists* (*n* = 30 for hepatocarcinogenicity, *n* = 16 for extrahepatic tumours)   None                            None                                        None                None                      30 of 30, in mice or rats   Typically pancreatic acinar cell and Leydig cell tumours. Thyroid and lung tumours and leukaemia also described.
  *PPAR*γ* agonists* (*n* = 5)                                                                 3 (mice, M and F)               1 (rats, M and F)                           None                3 (rats, M and F)         2 (rats and mice, F)        1 (mice, gallbladder adenoma). 1 (rats, stomach, leiomyosarcoma).
  *Dual acting PPAR*α*+*γ* agonists* (*n* = 6)                                                 5 (mice, M and F, hamster, M)   5 (rats, M and F)                           2 (rats, M and F)   2 (rats, mice, M and F)   3 (rats, mice, M and F)     1 (rats, testicular). 1 (rats, mammary). 1 (mice, mammary and stomach). 1 (rats, thyroid). 1 (rats, uterine). 1 (rats, uterine and leukaemia).

^(a)^Comparative data for PPAR selectivity are lacking. No study has to our knowledge for a panel of PPAR agonists compared activity on all PPAR isoforms, between rats, mice, and humans, in the relevant cell type, for example, hepatocyte or urothelial. However, it is clear that selective PPAR*γ* agonists may have significant PPAR*α* activity \[[@B3], [@B5], [@B9]\].

^(b)^ Mice appear to be more sensitive to the effect of PPAR*γ* agonists than rats \[[@B128]\].

^(c)^Rat urothelium may be more sensitive to the carcinogenic effect of dual-acting PPAR*α*+*γ* agonists than mouse urothelium. Bladder cancer was seen in SD, Wistar, and Fischer rats of both sexes \[[@B8]\]. Renal proximal tubular carcinoma was also observed with 2 dual agonists (undifferentiated sarcomatous tumours) \[[@B8]\].

^(d)^One dual-acting PPAR*α*+*γ* agonist for which fibrosarcoma has been described is tesaglitazar \[[@B15]\].

^(e)^One PPAR*γ* agonist for which hepatocarcinogenesis has been described is troglitazone \[[@B129]\].

^(f)^PPAR*α* and PPAR*γ* are typically described as having a tissue-restricted expression, with PPAR*β* expression being more ubiquitous \[[@B2], [@B95], [@B130]\]. Endothelial as well as urothelial cells coexpress PPAR*α* and PPAR*γ* isoforms \[[@B24]--[@B96]\]. White fat expresses mostly PPAR*γ* \[[@B2], [@B95], [@B130]\], but it is increasingly recognized that PPAR*α* may also have function in white fat \[[@B131]\]. Liver expresses mostly PPAR*α* \[[@B2], [@B95], [@B130]\], but it is increasingly recognized that PPAR*γ* may also have function in the liver \[[@B132]--[@B136]\].

[^1]: Recommended by Dipak Panigrahy
